- Home
- SABS vs NEUP Comparison
SABS vs NEUP Comparison
Compare SABS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- NEUP
- Stock Information
- Founded
- SABS 2014
- NEUP 1996
- Country
- SABS United States
- NEUP United States
- Employees
- SABS N/A
- NEUP N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- SABS Health Care
- NEUP
- Exchange
- SABS Nasdaq
- NEUP Nasdaq
- Market Cap
- SABS 15.8M
- NEUP 12.7M
- IPO Year
- SABS N/A
- NEUP N/A
- Fundamental
- Price
- SABS $2.64
- NEUP $7.72
- Analyst Decision
- SABS Strong Buy
- NEUP Strong Buy
- Analyst Count
- SABS 5
- NEUP 1
- Target Price
- SABS $11.80
- NEUP $21.00
- AVG Volume (30 Days)
- SABS 35.3K
- NEUP 30.4K
- Earning Date
- SABS 08-07-2025
- NEUP 08-15-2025
- Dividend Yield
- SABS N/A
- NEUP N/A
- EPS Growth
- SABS N/A
- NEUP N/A
- EPS
- SABS N/A
- NEUP 0.00
- Revenue
- SABS $377,835.00
- NEUP $15,662,715.00
- Revenue This Year
- SABS N/A
- NEUP N/A
- Revenue Next Year
- SABS N/A
- NEUP N/A
- P/E Ratio
- SABS N/A
- NEUP $4,532.08
- Revenue Growth
- SABS N/A
- NEUP N/A
- 52 Week Low
- SABS $1.00
- NEUP $2.90
- 52 Week High
- SABS $5.01
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- SABS 77.22
- NEUP N/A
- Support Level
- SABS $1.72
- NEUP N/A
- Resistance Level
- SABS $2.72
- NEUP N/A
- Average True Range (ATR)
- SABS 0.19
- NEUP 0.00
- MACD
- SABS 0.10
- NEUP 0.00
- Stochastic Oscillator
- SABS 91.89
- NEUP 0.00
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.